The federal frame
Peptide legality in the United States is governed primarily by federal law — specifically, section 503A of the Federal Food, Drug, and Cosmetic Act, which authorizes licensed pharmacies and physicians to compound medications for an individual patient under prescription. The Food and Drug Administration evaluates which bulk substances may be used in 503A compounding and places them in Category 1 (permitted pending rulemaking) or Category 2 (safety concerns identified).
That federal framework is the substantive answer to most "is peptide X legal in state Y" questions. State medical and pharmacy boards add a licensure layer — physicians must be licensed in the patient's state; pharmacies must be registered to ship into it — but states do not generally publish their own permitted-or-prohibited peptide lists.
What states actually control
What states actually control: who may practice medicine within their borders, who may operate a pharmacy, and how cross-state telehealth is handled. Some states are stricter on telehealth than others, but most operate within a similar framework: the prescribing physician must hold a license in the patient's state, and the pharmacy must comply with the destination state's pharmacy-board rules.
What states do not generally do: invent their own peptide-legality rules. When a state-level restriction exists, it's typically about scheduled substances, telehealth-prescribing requirements, or specific compounding standards (Massachusetts, post-NECC, has historically had stricter compounding oversight than average) — not "peptides are illegal here."
State legality, in most cases, is the wrong question. The substantive answer lives at the federal level — and the state question is mostly about who's licensed where.
State-by-state index
The 20 state guides below cover roughly two-thirds of the U.S. population and the highest-search-volume states for peptide-related queries. Each guide covers the federal frame, what's specific to that state's medical and pharmacy boards, and how telehealth prescribing works for residents.
| State | Population (rough) | State guide |
|---|---|---|
| California | 39M | Peptides legal in California, 2026 → |
| Texas | 30M | Peptides legal in Texas, 2026 → |
| Florida | 22M | Peptides legal in Florida, 2026 → |
| New York | 19M | Peptides legal in New York, 2026 → |
| Pennsylvania | 13M | Peptides legal in Pennsylvania, 2026 → |
| Illinois | 13M | Peptides legal in Illinois, 2026 → |
| Ohio | 12M | Peptides legal in Ohio, 2026 → |
| Georgia | 11M | Peptides legal in Georgia, 2026 → |
| North Carolina | 11M | Peptides legal in North Carolina, 2026 → |
| Michigan | 10M | Peptides legal in Michigan, 2026 → |
| Arizona | 7M | Peptides legal in Arizona, 2026 → |
| Washington | 8M | Peptides legal in Washington, 2026 → |
| Colorado | 6M | Peptides legal in Colorado, 2026 → |
| Massachusetts | 7M | Peptides legal in Massachusetts, 2026 → |
| Tennessee | 7M | Peptides legal in Tennessee, 2026 → |
| Virginia | 9M | Peptides legal in Virginia, 2026 → |
| New Jersey | 9M | Peptides legal in New Jersey, 2026 → |
| Indiana | 7M | Peptides legal in Indiana, 2026 → |
| Missouri | 6M | Peptides legal in Missouri, 2026 → |
| Maryland | 6M | Peptides legal in Maryland, 2026 → |
For a federal companion piece, see Are compounded peptides legal under the FDA? For tirzepatide-specific compounding state variation, see tirzepatide compounding by state, 2026.
How telehealth crosses state lines
Cross-state telehealth in the U.S. generally works through individual state licensure rather than a single federal license. A national telehealth platform is, in operational terms, a coordinated network of physicians who are each licensed in the states they serve. When a patient signs up, the platform routes them to a physician licensed in their state — that physician evaluates the intake, makes the prescribing decision, and signs the prescription.
Boswell operates this way. Each Boswell prescription for a state X resident is written by a physician licensed in state X, and dispensed by a 503A pharmacy registered to ship into state X. The how it works page details the full sequence.
Questions worth asking your provider
- Are you a physician licensed in my state?
- What is the current FDA bulk-substance category of the peptide you'd be prescribing?
- Is the pharmacy a 503A compounding pharmacy?
- How is the prescription evaluated — is there a real intake review, or is it form-only?
- Who follows up if I have a question or side effect after the medication arrives?
For deeper dives, see the provider comparison checklist and the sourcing and ordering guide.
Sources